Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

BACKGROUND: Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L., Andtbacka, Robert H. I., Collichio, Frances A., Wolf, Michael, Zhao, Zhongyun, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604502/
https://www.ncbi.nlm.nih.gov/pubmed/28923101
http://dx.doi.org/10.1186/s40425-017-0276-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604502/
https://www.ncbi.nlm.nih.gov/pubmed/28923101
http://dx.doi.org/10.1186/s40425-017-0276-8

Ejemplares similares